The Gene Scene: BRCA2

By Ambry Genetics

· 1 min. read

The Gene Scene: BRCA2
Source: Ambry Genetics

Pathogenic variants in the BRCA2 gene cause two distinct inherited conditions: an autosomal dominant cancer predisposition syndrome and an autosomal recessive form of Fanconi anemia. BRCA2-related cancer predisposition significantly elevates lifetime risks for breast, ovarian, pancreatic, and prostate cancers, among others. Individuals with biallelic BRCA2 variants face progressive bone marrow failure and increased malignancy risk.

Key points

  • BRCA2 encodes a breast cancer susceptibility protein on chromosome 13. The gene contains 26 coding exons and pathogenic variants follow either autosomal dominant or recessive inheritance patterns.
  • Female breast cancer risk reaches 55-69% cumulative lifetime risk in BRCA2 carriers. Additional elevated risks include male breast cancer (1.8-7.1%), ovarian cancer (13-29%), and pancreatic cancer (5-10%).
  • Contralateral breast cancer risk climbs to 26% within 20 years of initial diagnosis. This risk is age-dependent and more pronounced in individuals with earlier-onset disease, particularly before age 40.
  • BRCA2-related Fanconi anemia involves progressive bone marrow failure and growth deficiency. The condition can be confirmed through cytogenetic testing showing increased chromosomal breakage following specific chemical exposures.
  • Both germline and somatic BRCA2 alterations predict sensitivity to DNA-damaging chemotherapy agents. "Both germline and somatic alterations in the BRCA2 gene predict sensitivity to chemotherapy agents," supporting use of poly(ADP-ribose) polymerase inhibitor therapies in approved indications.
  • Reproductive couples with biallelic BRCA2 variants face 25% recurrence risk per pregnancy. Loss of function, with at least one hypomorphic allele, causes the Fanconi anemia phenotype.

Summarized by MalakyeAI

Links Cited on this Page